NantHealth Unveils Liquid GPS™, Powerful Next-Generation Tool for Blood-Based Tumor Profiling and Quantitative Monitoring
02 June 2018 - 9:00PM
Business Wire
Molecular test allows for continuous,
noninvasive monitoring and tumor profiling
NantHealth, Inc. (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company, unveiled Liquid
GPS™ a powerful next-generation tool for blood-based tumor
profiling and quantitative monitoring.
NantHealth chose the American Society of Clinical Oncology
(ASCO) 2018 Annual Meeting to showcase the potential of Liquid GPS™
— a blood-based molecular test that provides oncologists with a
powerful tool to continuously monitor and profile tumors, an
approach that is less invasive than a traditional biopsy.
Liquid GPS™ expands upon NantHealth’s molecular analysis
portfolio of products — which includes the tissue-based GPS Cancer
™ solution. Liquid GPS offers sophisticated analysis tools —
looking beyond cfDNA to cfRNA. This technology allows more
comprehensive profiling and trending of biomarkers that can’t be
assessed by cfDNA alone. As a result, Liquid GPS™ offers a richer
portrait of a patient’s condition and offers more therapeutic
targets, such as chemotherapy and immunotherapy, than a typical
liquid biopsy.
“We believe the development of Liquid GPS is important to our
broader vision for fighting cancer from a biological, rather than
an anatomical perspective,” said Dr. Patrick Soon-Shiong, CEO of
NantHealth “This test is a non-invasive way to achieve molecular
insights that could help shape treatment and provide the oncologist
and patients real-time information on the status of the cancer.
This work builds on what NantHealth has already done with GPS
Cancer as we focus on successfully analyzing and treating cancer at
the molecular level.”
More information about the significance and potential
applications of Liquid GPS™ please visit the NANT booth at
#7147
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-base, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth’s
focused portfolio exemplifies its unique systems-based approach to
personalized healthcare and integrates novel analysis with
large-scale, biometric and phenotypic data to track patient
outcomes and deliver precision medicine. For more information
please visit www.nanthealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180602005038/en/
NANT MEDIA CONTACTJen Hodson,
562-397-3639jhodson@nantworks.comorHenry Jackson,
310-486-8908cj@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024